Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Abeona Therapeutics Inc.

< Previous 1 2 Next >
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces Participation in November Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.